% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

biotuesday 6 posts  |  Last Activity: Oct 21, 2014 9:34 AM Member since: Oct 25, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Today's BioTuesdays feature article.

  • Amarantus Bioscience Holdings’ (OTCQB:AMBS) master services agreement with the lab services arm of ICON (NASDAQ:ICLR) puts Amarantus on the road to commercializing its LymPro diagnostic blood test for the early detection of Alzheimer’s disease (AD)…..

    See BT for rest of today's feature article on AMBS

  • Leerink Partners has upgraded Amicus Therapeutics (NASDAQ:FOLD) to “outperform” from “market perform” and raised its price target to $6 from $2.50.......

  • Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke patients, with data to be released before year end.

    “If we get the results we’re looking for, this could have a dramatic impact on stroke medicine and greatly improve treatment for more severe stroke patients,” chairman and CEO, Gil Van Bokkelen, says in an interview with BioTuesdays

    Cleveland-based Athersys is developing MultiStem for the treatment of conditions in the cardiovascular, neurological, inflammatory and immune disease areas.

    MultiStem is a biologic product manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. The stem cell product can be expanded on a large scale for future use and stored in frozen form until needed....

    See BioTuesdays for rest of this week's feature article on ATHX

  • Ladenburg Thalmann has initiated coverage of CombiMatrix (NASDAQ:CBMX) with a “buy” rating and price target of $3.40. The stock closed at $2.77 on Thursday.

    “We view CombiMatrix as an emerging leader in prenatal chromosomal microarray testing and products of conception for miscarriage management,” writes analyst Kevin DeGeeter.

    See BT for rest of brief....

  • CombiMatrix’s (NASDAQ:CBMX) strategic shift at the end of 2012 to focus its chromosomal microarray testing platform in the areas of prenatal genetics and pediatric development disorders is gaining traction with patients, physicians and payors.

    “We are a vastly different company from a year ago,” Mark McDonough, president and CEO, says in an interview with BioTuesdays. “We have a sharper focus, with millions more patients covered for microarray testing and numerous leading labs and physician groups now on board.”

    The Irvine, CA-based company specializes in miscarriage analysis, prenatal testing and pediatric genetics at its CLIA-approved lab. “We offer DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methods,” he adds.

    ....see BioTuesdays for the rest of tokay's feature on CBMX

2.08-0.07(-3.26%)Apr 1 4:00 PMEDT